MCID: DCT002
MIFTS: 36

Ductal Carcinoma in Situ malady

Cancer diseases category

Aliases & Classifications for Ductal Carcinoma in Situ

About this section

Aliases & Descriptions for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 8 10
 
Noninfiltrating Intraductal Carcinoma 61


Classifications:



External Ids:

Disease Ontology8 DOID:0060074

Summaries for Ductal Carcinoma in Situ

About this section
Wikipedia:64 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

MalaCards based summary: Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to breast cancer and breast ductal carcinoma. An important gene associated with Ductal Carcinoma in Situ is ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2). The compounds megestrol acetate and capecitabine have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related mouse phenotypes are digestive/alimentary and normal.

Related Diseases for Ductal Carcinoma in Situ

About this section

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 53)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer32.2PGR, ERBB2
2breast ductal carcinoma31.6TFF1, ERBB2, PGR
3breast disease31.1PGR, ERBB2
4papilloma30.6ACTC1, KRT14
5papillary carcinoma30.2PGR, KRT14, ERBB2, ACTC1
6gynecomastia10.7
7intraductal papilloma10.6
8lobular neoplasia10.6
9breast reconstruction10.6
10hypoxia10.5
11breast fibroadenoma10.4PGR
12leiomyomatosis10.4PGR
13retinoblastoma10.3
14obesity10.3
15poland syndrome10.3
16prolactinoma10.3
17pyoderma gangrenosum10.3
18comedo carcinoma10.3
19bilateral breast cancer10.3
20hidradenoma10.3
21neuroendocrine tumor10.3
22ovarian cyst10.3
23pyoderma10.3
24phyllode tumor10.3
25mammary paget's disease10.3PGR, ERBB2
26inflammatory breast carcinoma10.2ERBB2, PGR
27endometrial cancer10.2ERBB2, PGR
28gastric adenocarcinoma10.1TFF1, CLDN7, ERBB2
29spindle cell carcinoma10.1ACTC1, PGR
30adenosarcoma10.1PGR, ACTC1
31endometrial stromal sarcoma10.1ACTC1, PGR
32li-fraumeni syndrome10.1TFF1, PGR, ERBB2
33angiomyolipoma10.1ACTC1, PGR
34smooth muscle tumor10.1PGR, ACTC1
35bladder cancer, somatic10.0ERBB2, ACTC1
36leiomyosarcoma10.0ACTC1, PGR
37oxyphilic adenoma10.0KRT14, CLDN7
38malignant mixed mullerian tumor10.0PGR, ACTC1, ERBB2
39tubular adenocarcinoma10.0PGR, ACTC1, ERBB2
40myoepithelioma10.0ACTC1, KRT14
41fibromatosis10.0TFF1, PGR, ACTC1
42leiomyoma10.0PGR, ACTC1
43ovarian cancer, somatic9.9ERBB2, PGR, TFF1
44angiosarcoma9.9ACTC1, KRT14
45squamous cell carcinoma, head and neck9.9ERBB2, KRT14, CLDN7
46mucoepidermoid carcinoma9.9KRT14, ACTC1
47pleomorphic adenoma9.9ACTC1, ERBB2, KRT14
48salivary gland adenoid cystic carcinoma9.9ERBB2, KRT14, ACTC1
49lung cancer9.8ERBB2, SAGE1, TFF1, KRT14
50kidney cancer9.7CLDN7, KRT14, ACTC1

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to ductal carcinoma in situ

Symptoms for Ductal Carcinoma in Situ

About this section

Drugs & Therapeutics for Ductal Carcinoma in Situ

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Nolvadex13 38 TAMOXIFEN CITRATE AstraZeneca Approved October 1998
FDA Label: Nolvadex
Malady that Drug Treats: Breast Cancer
Indications and Usage:13 Metastatic Breast Cancer:; NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. In; premenopausal women with metastatic breast cancer, NOLVADEX is an alternative to; oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors; are estrogen receptor positive are more likely to benefit from NOLVADEX therapy.; Adjuvant Treatment of Breast Cancer:; NOLVADEX is indicated for the treatment of node-positive breast cancer in women following; total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some; NOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four or; more positive axillary nodes.; NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in women; following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.; The estrogen and progesterone receptor values may help to predict whether adjuvant; NOLVADEX therapy is likely to be beneficial.; NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvant; NOLVADEX therapy for breast cancer.; Ductal Carcinoma in Situ (DCIS):; In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated to; reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the; label). The decision regarding therapy with NOLVADEX for the reduction in breast cancer; incidence should be based upon an individual assessment of the benefits and risks of; NOLVADEX therapy.; Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patients; with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:; NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk for; breast cancer. This effect was shown in a study of 5 years planned duration with a median; follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The; longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or; breast cancer-related mortality (see BOXED WARNING at the beginning of the label).; NOLVADEX is indicated only for high-risk women.  High risk is defined as women at least; 35 years of age with a 5-year predicted risk of breast cancer e" 1.67%, as calculated by the Gail; Model.; Examples of combinations of factors predicting a 5-year risk e" 1.67% are:; Age 35 or older and any of the following combination of factors:; One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a; history of a breast biopsy showing atypical hyperplasia; or; At least 2 first degree relatives with a history of breast cancer, and a personal history of at; least one breast biopsy; or; LCIS; ; Age 40 or older and any of the following combination of factors:; One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first; live birth 25 or older, and age at menarche 11 or younger; or; At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or; younger; or; One first degree relative with a history of breast cancer, and a personal history of a breast; biopsy showing atypical hyperplasia.; ; Age 45 or older and any of the following combination of factors:; At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or; younger; or; One first degree relative with a history of breast cancer with a personal history of a benign; breast biopsy, age at menarche 11 or less and age at first live birth 20 or more.; ; Age 50 or older and any of the following combination of factors:; At least 2 first degree relatives with a history of breast cancer; or; History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or; older and age at menarche 11 or less; or; History of at least two breast biopsies with a history of atypical hyperplasia, and age at first; live birth 30 or more.; ; Age 55 or older and any of the following combination of factors:; One first degree relative with a history of breast cancer with a personal history of a benign; breast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live; birth 20 or older.; ; Age 60 or older and:; 5-year predicted risk of breast cancer e" 1.67%, as calculated by the Gail Model.; ; For women whose risk factors are not described in the above examples, the Gail Model is; necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail; Model Risk Assessment Tool by dialing 1-800-544-2007.; ; There are insufficient data available regarding the effect of NOLVADEX on breast cancer; incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific; recommendations on the effectiveness of NOLVADEX in these patients.; ; After an assessment of the risk of developing breast cancer, the decision regarding therapy with; NOLVADEX for the reduction in breast cancer incidence should be based upon an individual; assessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,; NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up period; of the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICAL; PHARMACOLOGY).
DrugBank Targets:11 1. Estrogen receptor; 2. Estrogen receptor beta; 3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase; 4. Protein kinase C
Mechanism of Action:13 
Target: estrogen receptors
Action: competitor with estraidiol
FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in; animal test systems. The antiestrogenic effects may be related to its ability to compete with; estrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of rat; mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of; already established DMBA-induced tumors. In this rat model, tamoxifen appears to exert its; antitumor effects by binding the estrogen receptors.; In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol for; estrogen receptor protein.

Drug clinical trials:

Search ClinicalTrials for Ductal Carcinoma in Situ

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

About this section

Anatomical Context for Ductal Carcinoma in Situ

About this section

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

31
Breast, Lymph node, Testes, Bone marrow, Bone, Smooth muscle, Salivary gland, Cervix, Monocytes

Animal Models for Ductal Carcinoma in Situ or affiliated genes

About this section

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.9TFF1, TNFRSF4, FOXC1, ERBB2, KRT14
2MP:00028738.4TNFRSF4, PGR, FOXC1, ACTC1, ERBB2
3MP:00107718.3KRT14, ERBB2, FOXC1, PGR, CLDN7, TFF1
4MP:00020068.3TFF1, TMEM158, PGR, ERBB2, KRT14
5MP:00053788.2KRT14, ERBB2, ACTC1, FOXC1, CLDN7, TNFRSF4
6MP:00053848.2TNFRSF4, PGR, FOXC1, ACTC1, ERBB2, KRT14
7MP:00053767.8TFF1, CLDN7, PGR, FOXC1, ACTC1, ERBB2

Publications for Ductal Carcinoma in Situ

About this section

Articles related to Ductal Carcinoma in Situ:

(show top 50)    (show all 714)
idTitleAuthorsYear
1
Histopathological characteristics of breast ductal carcinoma in situ and association with imaging findings. (25644245)
2015
2
Paget's disease of the male breast with underlying ductal carcinoma in situ ('DCIS'). (25832464)
2015
3
Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. (24948027)
2014
4
Molecular Pathology: SY18-1 MOLECULAR PROFILING OF BREAST DUCTAL CARCINOMA IN-SITU. (25188123)
2014
5
Post-operative radiotherapy for ductal carcinoma in situ of the breast. (24259251)
2013
6
Hypofractionated radiation therapy for breast ductal carcinoma in situ. (24113057)
2013
7
Patient, tumor and therapeutic features related to recurrence of ductal carcinoma in situ (DCIS). (24322025)
2013
8
Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. (23208501)
2013
9
US appearance of ductal carcinoma in situ. (23322838)
2013
10
Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype. (24029706)
2013
11
Factors influencing the quality of local management of ductal carcinoma in situ: a cohort study. (23737691)
2013
12
Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study. (23184608)
2013
13
Challenging paradigms: long non-coding RNAs in breast ductal carcinoma in situ (DCIS). (23577021)
2013
14
Molecular phenotypes of ductal carcinoma-in-situ and invasive ductal carcinoma: a comparative study. (22499299)
2012
15
Neuroendocrine ductal carcinoma in situ, comedo type, of the breast detected by screening mammography: a potentially pre-invasive counterpart of high grade neuroendocrine tumours. (22437750)
2012
16
Multi-institutional experience of ductal carcinoma in situ in black vs white patients treated with breast-conserving surgery and whole breast radiation therapy. (22672752)
2012
17
Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. (22795363)
2012
18
Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. (22134623)
2012
19
ACR appropriateness criteria(Ar) ductal carcinoma in situ. (22107336)
2012
20
Cell polarity, epithelial-mesenchymal transition, and cell-fate decision gene expression in ductal carcinoma in situ. (22577534)
2012
21
Breast cancer and ductal carcinoma in situ among women with prior squamous or glandular precancer in the cervix: a register-based study. (23011481)
2012
22
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. (21145284)
2011
23
Development and pilot testing of a communication aid to assist clinicians to communicate with women diagnosed with ductal carcinoma in situ (DCIS). (21088858)
2011
24
Intraoperative assessment of surgical margins during breast conserving surgery of ductal carcinoma in situ by use of radiofrequency spectroscopy. (21885281)
2011
25
Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast. (20701550)
2011
26
Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. (21493791)
2011
27
Mammographycally occult high grade ductal carcinoma in situ (DCIS) as second primary breast cancer, detected with MRI: a case report. (22933920)
2010
28
Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast. (20704578)
2010
29
Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. (21060026)
2010
30
Ductal carcinoma in situ: terminology, classification, and natural history. (20956817)
2010
31
Proceedings of the National Institutes of Health State-of-the-Science Conference, Diagnosis and Management of Ductal Carcinoma In Situ. September 2009. (21312388)
2010
32
Coronal serial sequential sampling of breast specimen in the assessment of the extent of ductal carcinoma in situ. (19722734)
2009
33
P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. (19190693)
2007
34
Ductal carcinoma in situ in BRCA mutation carriers. (17210933)
2007
35
Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. (16807982)
2006
36
Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? (15832086)
2005
37
Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. (15827818)
2005
38
S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. (15217497)
2004
39
p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. (15318938)
2004
40
Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. (14717665)
2004
41
Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. (14534730)
2003
42
Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. (12147647)
2002
43
Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast. (12016391)
2002
44
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. (11912139)
2002
45
Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. (12434415)
2002
46
p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. (11333292)
2001
47
Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. (11381366)
2001
48
Atypical cystic lobule of the breast: an early stage of low-grade ductal carcinoma in-situ. (11114859)
2000
49
Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. (9212742)
1997
50
Controversies in the treatment of ductal carcinoma in situ. (8610262)
1996

Variations for Ductal Carcinoma in Situ

About this section

Cosmic variations for Ductal Carcinoma in Situ:

6 (show all 31)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
144737TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
210701TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
310662TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
410867TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
543714TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
644901TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
711089TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
843559TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
910779TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
106932TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1143814TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1210660TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
13144210TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1410656TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1544415TP53breast,NS,carcinoma in situ,ductal carcinoma in situ3
1627541PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
171191159PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
1829326PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
19754PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
20776PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
21763PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
2229329PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
23775PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
2430744PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
25760PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
2629325PIK3CAbreast,NS,carcinoma in situ,ductal carcinoma in situ3
2733765AKT1breast,NS,carcinoma in situ,ductal carcinoma in situ3
2834142AKT1breast,NS,carcinoma in situ,ductal carcinoma in situ3
2919786CDH1breast,NS,carcinoma in situ,ductal carcinoma in situ3
30520KRASbreast,NS,carcinoma in situ,ductal carcinoma in situ3
3114060ERBB2breast,NS,carcinoma in situ,ductal carcinoma in situ3

Expression for genes affiliated with Ductal Carcinoma in Situ

About this section
Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for genes affiliated with Ductal Carcinoma in Situ

About this section

Compounds for genes affiliated with Ductal Carcinoma in Situ

About this section

Compounds related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 34)
idCompoundScoreTop Affiliating Genes
1megestrol acetate4410.1PGR, ERBB2
2capecitabine44 50 1112.1ERBB2, PGR
3anastrozole44 50 1112.1ERBB2, PGR
4exemestane44 50 60 1113.1PGR, ERBB2
5lapatinib44 50 1112.0PGR, ERBB2
62-methoxyethanol4410.0ACTC1, KRT14
7bisphenol a4410.0PGR, TFF1
8mucicarmine4410.0ACTC1, KRT14
9taxane4410.0ERBB2, PGR
10steroidal449.9TFF1, PGR
11leucovorin44 50 1111.9PGR, ERBB2
12diethylstilbestrol44 28 1111.9PGR, TFF1
13toremifene44 1110.9PGR, TFF1, ERBB2
14fulvestrant44 50 28 1112.8ERBB2, TFF1, PGR
15letrozole44 50 60 1112.8TFF1, PGR, ERBB2
16progestins449.8TFF1, PGR
174-hydroxytamoxifen449.8PGR, TFF1, ERBB2
18progestin449.8PGR, TFF1, ERBB2
19resveratrol44 60 24 1112.8PGR, ERBB2, TFF1
20hematoxylin449.8TFF1, ACTC1, KRT14
21raloxifene44 50 28 1112.8ERBB2, PGR
22retinoid449.5TFF1, PGR, KRT14
23trastuzumab44 50 1111.5ERBB2, PGR
24tamoxifen44 50 28 1112.4KRT14, TFF1, ERBB2, PGR
25testosterone44 60 24 1112.4ACTC1, PGR, TFF1, ERBB2
26genistein44 28 60 1 24 1114.4PGR, TFF1, ERBB2
27dexamethasone44 50 28 1112.3TFF1, ACTC1, PGR, ERBB2
28cyclosporin a44 28 6011.3TNFRSF4, ACTC1, PGR
29vegf449.3TFF1, ERBB2, PGR, ACTC1
30paraffin449.1ACTC1, ERBB2, PGR, KRT14, TFF1
31estrogen449.0PGR, TFF1, ACTC1, ERBB2, KRT14
32retinoic acid44 2410.0KRT14, PGR, TFF1, ACTC1
33steroid448.9ACTC1, TFF1, PGR, ERBB2, TAS2R64P
34progesterone44 28 60 24 1112.6TAS2R64P, KRT14, ERBB2, ACTC1, PGR, TFF1

GO Terms for genes affiliated with Ductal Carcinoma in Situ

About this section

Sources for Ductal Carcinoma in Situ

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet